[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618376":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":47,"studyPopulation":40,"armGroups":48,"interventions":55,"overallOfficials":61,"centralContacts":66,"locations":72,"responsibleParty":89,"collaborators":40,"id":91,"slug":40,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":40,"enrollmentInfo":100,"targetDuration":40,"studyType":103,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":114,"whyStopped":40,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Cardionovum GmbH","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":40},[9,13],{"measure":10,"description":11,"timeFrame":12},"Technical Success","Ability to cross the lesion and fully efface the balloon, leaving no residual stenosis (\\\u003C30%) evaluated by fistulography","At the end of the procedure (up to 40 minutes)",{"measure":14,"description":15,"timeFrame":16},"Freedom from procedure-related complications after 1 month","freedom from adverse events related to the procedure in 1 month follow up period","1 month",[18,21,24,28,31,34,37],{"measure":19,"description":20,"timeFrame":12},"Acute Device Success","successful delivery, balloon inflation, deflation, and retrieval of the intact study device without burst below rated burst pressure",{"measure":22,"description":23,"timeFrame":12},"Clinical Success","after intervention, the function of hemodialysis access is improved, dialysis function is restored, and at least one complete dialysis session has been completed",{"measure":25,"description":26,"timeFrame":27},"Procedural Surgery success","Once technical success has been achieved, no major adverse events (MAE) occurred during the procedure or hospitalization, including death, stroke, thrombosis, allergic reactions, or pulmonary disease","At the end of hospitalization (assessed up to 5 days)",{"measure":29,"description":30,"timeFrame":16},"Target Lesion Primary Patency","Primary patency rate refers to the peak systolic velocity ratio (PSVR) measured by Doppler ultrasound (DUS) ≤ 2.0, which confirms the absence of restenosis and does not require clinically driven target lesion revascularization (CD-TLR)",{"measure":32,"description":33,"timeFrame":16},"Freedom from target lesion revascularization","Clinical symptoms and dialysis indicators indicate that dialysis cannot be successfully performed, and the target lesion location (confirmed by Doppler ultrasound) +\u002F-5 mm proximal\u002Fdistal requires re-intervention surgery",{"measure":35,"description":36,"timeFrame":16},"Major Adverse Events (MAE)","Occurrence of major adverse events (MAE)",{"measure":38,"description":39,"timeFrame":16},"Dialysis Circuit Patency","Patency of the whole patency circuit evaluated at Doppler Ultra-Sound (DUS)",null,{"allocation":42,"interventionModel":43,"interventionModelDescription":40,"primaryPurpose":44,"observationalModel":40,"timePerspective":40,"maskingInfo":45},"NA","SINGLE_GROUP","TREATMENT",{"masking":46,"maskingDescription":40,"whoMasked":40},"NONE","First-In-Man Single Site study to assess safety and efficacy of ultra-high pressure PTA balloon called ULTRAVIOLET UHP PTA in treating resistant stenotic lesions in arterio-venous fistula of dialysis patients.",[49],{"label":50,"type":51,"description":52,"interventionNames":53},"ULTRAVIOLET UHP PTA","EXPERIMENTAL","Percutaneous transluminal angioplasty with ultra-high-pressure balloon",[54],"Device: PTA balloon",[56],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":40},"DEVICE","PTA balloon","Angioplasty of a resistant stenotic lesion in the arterio-venous fistula",[50],[62],{"name":63,"affiliation":64,"role":65},"Matteo Tozzi, MD, PhD","Universita' Insubria, ASST Sette Laghi, Varese, Italy","PRINCIPAL_INVESTIGATOR",[67],{"name":68,"role":69,"phone":70,"phoneExt":40,"email":71},"Paolo Silvestri, MSc","CONTACT","+393451016383","paolo.silvestri@cardionovum.com",[73],{"facility":74,"status":40,"city":75,"state":40,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"ASST Sette Laghi","Varese","21100","Italy","IT",{"type":80,"coordinates":81},"Point",[82,83],8.82511,45.82058,{"lat":83,"lon":82},[86],{"name":63,"role":69,"phone":87,"phoneExt":40,"email":88},"0039 0332 393259","matteo.tozzi@me.com",{"type":90,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100618376",false,"NCT07330817","A First-In-Man Study to Assess Safety and Efficacy of Ultra High Pressure PTA Balloon ULTRAVIOLET in Treating A-V Fistula Stenosis","ULTRAVIOLET FIM_A First-In-Man Single Arm Prospective Single Center Study to Assess Safety and Efficacy of Ultra High Pressure PTA Balloon ULTRAVIOLET in Treating A-V Fistula Stenosis","ULTRAVIOLETFIM","Inclusion Criteria:\n\n* Patients able to understand the purpose of the study, voluntarily agree to participate and signed Informed Consent form\n* Patients with impaired haemodialysis access due to narrowed lesions, as indicated by contrast or ultrasound or clinical diagnosis.\n* Indications for percutaneous endovascular therapy with diameter stenosis \\>50% and fistula's hemodynamic showing abnormalities (thrombosis in the AVF, high venous pressure, re-circulation, abnormal physical examination, decrease in dialysis efficiency, decrease in blood flow through the vascular access)\n* Target lesion is a resistant de novo or restenotic lesion\n* The target lesion is located in the reflux vein from the anastomotic site of arteriovenous fistula (AVF) to the distal end of the subclavian vein (excluding the anastomotic site of AVF); if there are no target lesions, they should be treated with standard angioplasty balloon before treating the target lesion.\n\nExclusion Criteria:\n\n* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrolment into this study;\n* Patients who are actively participating in another drug or device investigational study, who have not completed the primary endpoint follow-up period;\n* Patients who have undergone major surgical procedures (such as open chest surgery, head surgery) within 30 days before being enrolled in the study;\n* Patients who plan to undergo major surgical procedures (such as open chest surgery, head surgery) within 30 days after being enrolled in the study;\n* Immature AVF (not used for dialysis; due to insufficient inner diameter, inability to ensure successful puncture, and inadequate blood flow, this access has not been used for successful dialysis);\n* AVF has been implanted with a stent.","ALL","18 Years",{"count":101,"type":102},35,"ESTIMATED","INTERVENTIONAL",[42],"First-In-Man Single Arm Prospective Study to assess the safety and efficacy of ULTRAVIOLET UHP PTA balloon.",[107,108],"Arterio-venous Fistula","Stenosis of Arteriovenous Dialysis Fistula",[110,111,112,58,113],"A-V fistula","First-In-Man","Ultra-High Pressure Balloon","Resistant Stenotic Fistula","NOT_YET_RECRUITING","2025-12-29",{"date":117,"type":118},"2026-01-09","ACTUAL",{"date":120,"type":102},"2026-02",{"date":122,"type":102},"2027-02",{"name":5,"class":6},1]